Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Discovery of T-cell 'traffic control' boosts new drug promise

Discovery of T-cell 'traffic control' boosts new drug promise

July 15, 2005

Scientists have begun to clarify how one of the body's molecules controls the trafficking of T cells through the blood, lymph nodes and on to tissues to fight infection - a crucial response that sometimes goes awry, attacking the body's own tissues and causing autoimmune diseases.

The traffic control system - composed of a fat-like compound called S1P and its receptor on T cells - usually prevents T cells from launching harmful reactions. But when the S1P traffic cop reacts incorrectly, T cells can swamp healthy tissue. The new research explains how a promising experimental drug treats the autoimmune disease multiple sclerosis by blocking excess S1P action. The research also shows the promise of similar strategies to prevent rejection of transplanted organs and tissues without compromising essential immune defenses.




The emerging view brings together research findings on S1P's effect on both the immune system and the blood-circulating vascular system, showing how the two systems interact to regulate T cell circulation and prevent a constant and potentially dangerous release of T cells, or lymphocytes.

The research is presented this month in a special issue of Nature Reviews Immunology. Authors are Edward Goetzl, MD, at UCSF and Hugh Rosen, MD, PhD, at the Scripps Research Institute, scientists who have pioneered the new understanding. Goetzl is the Robert L. Kroc Professor of Medicine and Immunology at UCSF. Rosen is a professor of immunology at Scripps.

Goetzl and Rosen participated in the discovery of S1P's role in T cell trafficking. Goetzl has also shown that S1P regulates T cell trafficking by occupying a receptor on the T cell surface that suppresses the cells' normal response to a "forward march" signal.

T cells respond by chemotaxis - moving from areas of lower to higher concentration of a signaling molecule known as a chemokine. Studies by the two scientists have shown that S1P and its T cell receptors block this signaling. They slow the flood of T cells "called into" lymph nodes by chemokines.

The scientists made a second discovery about T cell movement: S1P, like chemokines, can also act as a chemotactic attractant to T cells. Once T cells enter lymph nodes - the sites where they encounter antigens for microbes and other infectious agents - they sense S1P in the outflowing blood and so migrate into the blood and onto tissues where they are needed to fight infection.

In a key experiment, Goetzl's and Rosen's labs showed that by chemically displacing S1P, its natural braking effect is released, stimulating T cell traffic into lymph nodes. Because this also blocks S1P's chemotactic influence, migration of T cells out of the lymph nodes is greatly reduced. T cells are essentially sequestered in the nodes. Such an effect would prevent T cells from swamping newly transplanted organs or launching a harmful autoimmune reaction, the scientists suggest in the paper.

They think this mechanism underlies the promising clinical trial results of a new drug against multiple sclerosis (MS) recently reported by other researchers. That study showed that the experimental drug, FTY720, significantly reduced the destructive autoimmune process in patients with MS, a debilitating disease in which the body's T cells attack the myelin coating of nerve cells and disrupt their function. Neither Goetzl nor Rosen is involved in the on-going clinical trials of the new drugs and neither has financial ties to the companies that manufacture them.

Controlling this process with drugs offers "enormous potential" against devastating immune reactions, Goetzl says.

"Transplanting organs or even cells, such as insulin-producing Beta cells, into a patient triggers immune reactions that reject the transplant, but a drug such as FTY720 controls S1P function and slows the rush of T cells to the transplantation site without blocking normal immune response against bacteria and other infectious agents," he says. Similarly, such a drug should slow the autoimmune response that occurs in MS, a hypothesis recently confirmed in phase 2 clinical trials, he says.

Such drugs do not interfere with essential protective immune function since bacterial proteins that normally trigger immune defense do so when they enter lymph nodes - "where the T cells are essentially trapped by the drug for a few days, but still are working fine and allowing new antibody formation," he explains.

Treatment using this drug strategy does not come without risks, Goetzl cautions. Current drugs that affect one type of S1P receptor affect all others as well, and some of these control heart rate and muscle development. In clinical trials of some of these kinds of drugs, a number of patients have tired easily, experienced lower blood flow and a tendency for airways to constrict as muscle walls develop abnormally, Goetzl says.

"Fully exploiting this approach for treatment of autoimmune diseases and transplant rejection will depend on developing new drugs that block only the immune type of S1P receptor," he adds. "But early studies by a number of researchers are quite promising."

Progress will also come from finding "uniquely effective combinations of these agents with other immunosuppressive drugs," he says.

In animal studies and clinical research with patients over more than a decade, scientists have come to understand that millions of T cells and B cells are "called" into lymph nodes by other immune molecules called chemokines.

"But we began to wonder why T cells don't always swarm into lymph nodes and flood on into blood vessels that lead to all parts of the body," Goetzl says. "We asked ourselves, 'What is the brake?'"

In research with mice that have T cells that lack S1P receptors or have over-expressed receptors, the Goetzl and Rosen labs and others determined that T cells have on their surfaces what are known as G protein-coupled receptors, which when occupied by chemokines - their natural binding partners - prompt the T cells to rush into lymph nodes. But S1P, they found, can act through its own G-coupled receptors to prevent chemokines from triggering T cell movement. In ways not yet fully understood, this process is reversible, providing the body with a crucial control over when and how much of the potent T cell soldiers to release into the blood stream.

University of California-San Francisco



Related Autoimmune Diseases Current Events and Autoimmune Diseases News Articles Autoimmune Diseases Current Events and Autoimmune Diseases News RSS Autoimmune Diseases Current Events and Autoimmune Diseases News RSS
Researchers find new way to attack inflammation in Graves' eye disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.

National report shines light on lupus 50-year treatment drought
Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award.

Master gene that switches on disease-fighting cells identified by scientists
The master gene that causes blood stem cells to turn into disease-fighting 'Natural Killer' (NK) immune cells has been identified by scientists, in a study published in Nature Immunology today.

Endothelin-Related Drugs Benefit Patients With Pulmonary Hypertension
Recent research to block the effects of endothelin, a powerful substance that constricts blood vessels and stimulates cell growth, has led to successful treatment of pulmonary arterial hypertension and provides hope for treating other chronic diseases.

Promising new target emerges for autoimmune diseases
University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells.

Blood pressure medication to treat multiple sclerosis?
Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team in cooperation with scientists from Stanford University in California.

Taking the Needle's Sting Out of Diabetes
Found in 30% of all human cancer tumors, the Ras protein literally "drives cells crazy," says Prof. Yoel Kloog, the dean of the Faculty of Life Sciences at Tel Aviv University. Prof. Kloog was the first in the world to develop an effective anti-Ras drug against pancreatic cancer, currently in clinical trials.

Sun exposure may trigger certain autoimmune diseases in women
Ultraviolet (UV) radiation from sunlight may be associated with the development of certain autoimmune diseases, particularly in women.

The right messenger for a healthy immune response
Researchers from the Molecular Immunology group at the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now shown that Beta-Interferon also plays a crucial role during an immune response: without Beta-Interferon immune cells are unable to show "wanted posters" of pathogens to other cells.
More Autoimmune Diseases Current Events and Autoimmune Diseases News Articles
Living Well with Autoimmune Disease: What Your Doctor Doesn't Tell You...That You Need to Know

Living Well with Autoimmune Disease: What Your Doctor Doesn't Tell You...That You Need to Know
by Mary J. Shomon (Author)

Are you tired? Achy? Depressed? Overweight?
You could be suffering from an autoimmune disease.

Autoimmune disease is the third major category of illness in the United States, yet very little is known about the many serious and chronic immune conditions. If you're one of the 50 million Americans suffering from one kind of autoimmune disease-whether it's lupus, rheumatoid arthritis, multiple sclerosis, thyroid disease, fibromyalgia, chronic fatigue syndrome, or Crohn's disease-there's a good chance you'll develop another.

This book can help.

Written by Mary J. Shomon, a well-known patient advocate who was diagnosed with autoimmune disease in 1995, this guide to alternative and natural remedies shows you how to treat the underlying causes of immune system...

Anti-Aging Vibes Rhodiola Rosea Nutrition Supplement, 60 Capsules

Anti-Aging Vibes Rhodiola Rosea Nutrition Supplement, 60 Capsules
by Anti-Aging Vibes

For centuries, the herb Rhodiola has been used in traditional medicine in Russia, Scandinavia, and other countries, and is a perfect candidate for supplementing the Anti-Aging Vibes Core Program. Rhodiola is a powerful "adaptogenic" herb, meaning that it has a broad range of actions with no known downsides In fact, Mongolian doctors used it to support healthy lung and cell function.* Further research shows that it protects from mental and physical stress, toxins, and cold temperature stress.*

Rhodiola Rosea contains active ingredients that are responsible for its wide range of beneficial actions. Anti-Aging Vibes Rhodiola is "standardized" to contain at least 3 percent rosavin, the primary active compound in the herb. Rosavin doesn't account for all of the herb's activity and our...

The Autoimmune Epidemic

The Autoimmune Epidemic
by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword)

From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center

"The Autoimmune Epidemic by Donna Jackson Nakazawa is an astounding book....It is the kind of book that will rivet you and scare you. It will make you angry. It will amaze you with the courage of some of the people described in the book...The Autoimmune Epidemic is every bit as compelling as Upton Sinclair's The Jungle...It is also every bit as necessary as An Inconvenient Truth....

You will leave this book with no reservations about the veracity of the conclusions: put simply, there is no doubt that autoimmune diseases are on the rise and increasing environmental exposures of toxins and chemicals is fueling this rise. The research is sound. The conclusions unassailable....

Reading The...

Unlocking the Mystery of Wheat and Gluten Intolerance

Unlocking the Mystery of Wheat and Gluten Intolerance
Also With: Dr. Thomas O'Bryan (Host), Sueson Vess (Host)

This 2-plus hour DVD of the June 17,2006 seminar at College of DuPage, Glen Ellyn, IL is a valuable learning tool for those interested in gluten intolerance and the connection to autoimmune diseases. Learn how to implement and follow a gluten-free diet for improved health and wellness. In sensitive individuals, gluten intolerance triggers Auto-Immune Diseases, Attention Deficient Disorders, Epilepsy, Multiple Sclerosis, Migraines, Chronic Fatigue Syndrome, and more. During this seminar, learn how all may be related to gluten intolerance.

What Your Doctor May Not Tell You About Autoimmune Disorders: The Revolutionary, Drug-Free Treatments for Thyroid Disease, Lupus, MS, IBD, Chronic Fatigue; Rheumatoid Arthritis, and Other Diseases

What Your Doctor May Not Tell You About Autoimmune Disorders: The Revolutionary, Drug-Free Treatments for Thyroid Disease, Lupus, MS, IBD, Chronic Fatigue; Rheumatoid Arthritis, and Other Diseases
by Stephen B. Edelson (Author), Deborah Mitchell (Author)

Autoimmune disorders are not well understood and therefore difficult to treat. The result is that there are millions of Americans who are suffering because they aren't being diagnosed properly, or getting the correct medical treatment they need. Here, Dr. Edelson discusses the most common types of autoimmune diseases, including lupus, Chron's disease, thyroid disease, rheumatoid arthritis, and chronic fatigue syndrome, outlining their symptoms, causes, and risk factors. He describes his own revolutionary program for treating the root of all autoimmune disorders-without drugs-providing readers with new hope for getting back on the road to better health.

  Immunol Focus Autoimmune Video 5 [VHS]
Starring: Johnstone



Gastric Gold Aloe Vera AMP 90 Count Bottle

Gastric Gold Aloe Vera AMP 90 Count Bottle
by Alternative Health Products

Gastric Gold is helpful in reversing and correcting many digestive and gastrointestinal tract disorders and diseases. A.M.P. (Aloe Mucilaginous Polysaccharide) the main ingredient in Gastric Gold purifies the blood, cleanses the liver, restores and protects the digestive tract, while it works to stop the damaging causes of these painful conditions: The Aloe Vera plant has been recognized for many years for its remarkable health-enhancing properties. In the past it was known for external applications for the skin only. Concentrated and stabilized Aloe (AMP) the active ingredient in Gastric Gold, is now widely used to help a variety of conditions in the digestive tract. The digestive tract is designed to ensure nutrients from food are absorbed into the blood stream while dispensing with...

Recovery SA Freedom to Move, Powder 1 Kg

Recovery SA Freedom to Move, Powder 1 Kg
by Biomedica Nutraceutical Medicine Company

Recovery SA is an oral anti-inflammatory / anti-catabolic used primarily to improve surgical recovery and disease tissue breakdown, inflammation and pain associated with chronic degenerative conditions, such as arthritis and autoimmune diseases.

Wampole ELISA II Test Kits, SS-A (Ro) II - Autoimmune Disease Kits - Model 437070CE

Wampole ELISA II Test Kits, SS-A (Ro) II - Autoimmune Disease Kits - Model 437070CE
by Inverness Medical

These enzyme-linked immunosorbent assay (ELISA) test kits are capable of being run in a manual, semi-automated, or fully automated capacity with customized instrumentation packages available to suit individual laboratory needs. Kits come in breakaway, removable test wells in a microplate format, with color-coded, ready-to-use reagents. Assays use interchangeable substrate, stop solution, and wash buffer. This uniformity of reagents allows for ease of automation with microtiter processing systems. Kits provide flexible testing with simple procedures, a broad menu, and accurate results. The autoimmune disease kits offer a wide range of ELISA tests, including an antinuclear antibody (ANA) screen, specific reflex tests, and extractable nuclear antibody (ENA) kits. Enteric disease kits...

Body Wars (non-profit)

Body Wars (non-profit)
Starring: Adam Harrington
Directed By: Glenn Krawczyk
Also With: Glenn Krawczyk (Writer), Stephen H. Schwartz (Producer), Andrew Waterworth (Producer), Michael Stedman (Producer)



© 2009 BrightSurf.com